Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 330 participants.

Also called NCT06954155

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 330 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06954155
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06954155. Randomized; single masking; primary purpose treatment. Start 2025-05-30 (actual); primary completion 2027-02-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND
Acronym
TRACE-BEYOND
Condition
Stroke
Intervention (Drug)
Tenecteplase (0.25mg/kg)
Intervention (Drug)
Standard medical treatment
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct06954155
Content hash
1ea6e5d2887cb18d89796b418165233b5138974f71f08692cd8e805ebf7949c5